Abstract
Subcutaneous immunoglobulin therapy (SCIG) offers an opportunity for patients with primary immunodeficiencies (PIDD) to self-infuse at home, potentially reducing treatment burden and improving satisfaction. This study assessed overall patient experience and treatment satisfaction with an investigational 20% subcutaneous immunoglobulin (Ig) therapy (Human Immune Globulin Subcutaneous, 20% [SCIG 20%]).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
